四环医药(00460)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00460 四环医药

休市中 07-24 16:08:05

0.880

-0.020

-2.22%

最高0.890	最低0.870	成交量981.20万
今开0.890	昨收0.900	日振幅2.22%
总市值80.31亿	流通市值80.31亿	总股本91.26亿
成交额862.56万	换手率0.11%	流通股本91.26亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00460","market":"HK","secType":"STK","nameCN":"四环医药","latestPrice":0.88,"timestamp":1784880485002,"preClose":0.9,"halted":0,"volume":9812000,"delay":0,"changeRate":-0.02222222222222224,"floatShares":9126000000,"shares":9126000000,"eps":0.022805102889049217,"marketStatus":"休市中","change":-0.02,"latestTime":"07-24 16:08:05","open":0.89,"high":0.89,"low":0.87,"amount":8625560,"amplitude":0.022222,"askPrice":0.88,"askSize":1816000,"bidPrice":0.87,"bidSize":1578000,"shortable":3,"etf":0,"ttmEps":0.02280394526961323,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785115800000},"marketStatusCode":7,"adr":0,"listingDate":1288195200000,"exchange":"SEHK","adjPreClose":0.9,"dividendRate":0.025523,"openAndCloseTimeList":[[1784856600000,1784865600000],[1784869200000,1784880000000]],"volumeRatio":0.41149022628113074,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00460","defaultTab":"news","newsList":[{"id":"2653322294","title":"【券商聚焦】长城证券首予四环医药(00460)买入评级 指医美业务成核心支柱","url":"https://stock-news.laohu8.com/highlight/detail?id=2653322294","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653322294?lang=zh_cn&edition=full","pubTime":"2026-07-21 15:32","pubTimestamp":1784619134,"startTime":"0","endTime":"0","summary":"医美业务已成为公司核心支柱，2025年实现收入14.85亿元，同比大增99.6%，营收占比首次超过50%。核心代理产品“乐提葆”肉毒毒素质价比突出，2025年销量突破120万瓶，同比增长超50%，已覆盖全国超8000家医美机构。医药业务方面，创新药正成为第二增长曲线。长城证券看好公司医美业务进入快速放量阶段及医药业务盈利改善，预测其2026-2028年归母净利润分别为6.09亿元、9.24亿元、12.63亿元，对应PE为11.41倍、7.52倍、5.50倍，首次覆盖给予“买入”评级。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986407","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","KCE","002939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651261351","title":"港股异动 | 四环医药(00460.HK)早盘涨超12% 四环医药渼颜空间冻妍临床研究成果荣登国际SCI期刊","url":"https://stock-news.laohu8.com/highlight/detail?id=2651261351","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651261351?lang=zh_cn&edition=full","pubTime":"2026-07-14 11:17","pubTimestamp":1783999053,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1593","BK1515","BK1600","00460","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651139126","title":"港股异动 | 四环医药(00460)早盘涨超12% 四环医药渼颜空间冻妍临床研究成果荣登国际SCI期刊","url":"https://stock-news.laohu8.com/highlight/detail?id=2651139126","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651139126?lang=zh_cn&edition=full","pubTime":"2026-07-14 11:17","pubTimestamp":1783999053,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，四环医药早盘涨超12%，截至发稿，涨8.33%，报0.91港元，成交额5161.24万港元。消息面上，近日，由四环医药渼颜空间牵头，携手全国多家公立医院与头部医美机构共同完成的冻妍临床研究，取得重要学术成果。相关研究论文正式发表于皮肤科领域国际权威SCI期刊《Journal of Cosmetic Dermatology》。这一成果不仅为冻妍注入了高质量的临床循证证据，更标志着其在提升皮肤质量方面的疗效获得国际学术界的高度认可。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4588","BK1600","BK1593","BK1515","VXUS","KCAI","00460","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651289171","title":"【券商聚焦】中信证券：预计美妆行业在次季延续低速增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2651289171","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651289171?lang=zh_cn&edition=full","pubTime":"2026-07-14 08:55","pubTimestamp":1783990545,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研究指，22026Q2，预计美妆行业在需求疲弱、流量成本走高、内容运营压力加大的背景下延续低速增长；结构性进一步分化，国际高端品牌销售反弹，本土大众、中端定位品牌承压；毛戈平、林清轩延续高增长，巨子生物、贝泰妮、敷尔佳销售底部回升。2026Q2，医美板块上游产品供给增加，竞争延续较高强度，四环医药受益于自主产品上市继续提升市场份额。估值已充分反映当前的经营压力且已严重低估，静候基本面改善和估值回升。","market":"other","thumbnail":"https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985765","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1516","BK1600","01530","BK1521","LU1997244956.HKD","BK1147","02373","LU1720050803.USD","LU1997245094.SGD","BK0276","LU1064131003.USD","06699","LU1655091616.SGD","LU0405327148.USD","LU1997245177.USD","BK1564","BK1215","LU2495084118.USD","02367","02196","BK0188","01696","600030","BK0183","BK1515","LU2488822045.USD","LU0405327494.USD","LU1328615791.USD","BK0012","BK1585","LU1794554557.SGD","KCE","LU1580142542.USD","00460","BK0196","LU2148510915.USD","06030","BK1100","SG9999004311.SGD","02138","BK1207","BK1587","BK0028","BK1161","LU2289578879.USD","LU1064130708.USD","LU1255011170.USD","BK1511","HK0000165453.HKD","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649954218","title":"创新药板块走低 科伦博泰生物(06990)跌7.67% 当前板块仍处估值修复行情","url":"https://stock-news.laohu8.com/highlight/detail?id=2649954218","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649954218?lang=zh_cn&edition=full","pubTime":"2026-07-08 11:08","pubTimestamp":1783480087,"startTime":"0","endTime":"0","summary":"有研究指，创新药板块年内曾两轮短期反弹，本轮行情依托政策组合、高含金量海外交易、机构持续加仓三大不同支撑，但机构表示当前仅为估值修复行情，基本面全面反转仍需中期、三季度财报验证，后续走势重点跟踪企业盈利兑现与CGT正式政策落地进度。","market":"us","thumbnail":"https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985359","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0456846285.SGD","BK1600","LU0588546209.SGD","06955","01952","SG9999014674.SGD","LU0516423091.SGD","02268","LU0348784397.USD","LU0979878070.USD","01672","LU0051755006.USD","LU2476274308.USD","09926","LU2242644610.SGD","LU0819121731.USD","02359","LU0140636845.USD","MEDX","SG9999002463.SGD","02269","06990","BK1515","BK1191","01477","LU1880383366.USD","BK1521","LU0417516571.SGD","KURE","LU0320764599.SGD","LU0326950275.SGD","159992","06978","02186","IE00B0JY6N72.USD","LU0516422440.USD","LU0572944931.SGD","LU1046422090.SGD","REVS","LU0348783233.USD","00460","IBBQ","LU0196878994.USD","BK1583","LU3063872942.SGD","LU0052750758.USD","01530","06855","CZA","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167410152","title":"四环医药6月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1167410152","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167410152?lang=zh_cn&edition=full","pubTime":"2026-07-03 16:37","pubTimestamp":1783067842,"startTime":"0","endTime":"0","summary":"四环医药控股集团有限公司于2026年7月3日发布截至2026年6月30日止月份的证券变动月报表。公告显示，公司法定股本与已发行股份结构在6月保持稳定，没有新增发行、购回或注销等活动。本月亦无因此所发行的新股和转让库存股份，相关购股权仍维持不变。公告指出，截至报告期末，公司已满足香港联交所对公众持股量的要求，股本于6月期间未发生任何变动。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102112303","title":"四环医药宣派末期股息每股1.09港仙，7月16日派发","url":"https://stock-news.laohu8.com/highlight/detail?id=1102112303","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102112303?lang=zh_cn&edition=full","pubTime":"2026-06-26 16:46","pubTimestamp":1782463590,"startTime":"0","endTime":"0","summary":"四环医药(00460)公布，公司在2026年6月26日举行的股东周年大会上，正式批准派发截至2025年12月31日止年度的末期现金股息。每股股息为人民币0.96分，将按中国人民银行公布的汇率中间价折算为港元派付，折合每股1.09港仙。\n股权登记日定为2026年7月6日，凡于当日名列公司股东名册的股东，均有权收取末期股息。股息款项将于2026年7月16日派发。\n此次末期股息方案以逾99.99%的赞成票获得通过，反映股东对议案的高度支持。公司亦在股东大会上通过了重选董事、续聘核数师及多项股份发行与回购授权等决议案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"四环医药宣派末期股息每股1.09港仙，7月16日派发","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643093780","title":"医美概念股普跌 三生制药(01530)下挫5.67% 机构指市场逐步由流量竞争转向品牌竞争","url":"https://stock-news.laohu8.com/highlight/detail?id=2643093780","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643093780?lang=zh_cn&edition=full","pubTime":"2026-06-16 10:25","pubTimestamp":1781576726,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医美概念股普跌，截至发稿，三生制药(01530)跌5.67%，四环医药(00460)跌4.30%，巨子生物(02367)跌2.06%，复锐医疗科技(01696)跌1.98%，山东新华制药股份(00719)跌1.91%，昊海生物科技(06826)跌1.90%。消息面上，华龙证券表示，行业层面，医美市场逐步由流量竞争转向品牌竞争，精细化运营及长期用户管理成为机构提升竞争力的重要方向。产品层面，胶原蛋白注射产品商业化落地持续推进，行业发展重心正由传统填充向组织修复、皮肤质量改善及长期抗衰升级。长期来看，具备核心研发能力及品牌运营优势的企业有望持续受益于行业高质量发展趋势。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250110/NDE0ZmVkNmQ0OWQ1YWQ5ZWU5ODBlOTBjYzlmMjcxMzI0MDU1NzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NDE0ZmVkNmQ0OWQ1YWQ5ZWU5ODBlOTBjYzlmMjcxMzI0MDU1NzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983863","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","BK1100","01696","BK1191","06826","BK1515","SG9999004311.SGD","BK1593","BK1600","00460","BK1207","BK1585","HK0000165453.HKD","02367","00719","BK1161","BK1583","01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641248973","title":"四环医药(00460)：受托人就股份奖励计划购买合共500万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2641248973","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641248973?lang=zh_cn&edition=full","pubTime":"2026-06-08 19:41","pubTimestamp":1780918873,"startTime":"0","endTime":"0","summary":"智通财经APP讯，四环医药(00460)发布公告，于2026年6月8日，受托人已就2022年股份奖励计划于市场上购买合共500万股本公司股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451577.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1600","BK1593","BK1515","00460","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640016229","title":"四环医药(00460)：受托人就股份奖励计划购买合共1000万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2640016229","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640016229?lang=zh_cn&edition=full","pubTime":"2026-06-03 19:59","pubTimestamp":1780487960,"startTime":"0","endTime":"0","summary":"智通财经APP讯，四环医药(00460)发布公告，于2026年6月3日，受托人已就股份奖励计划于市场上购买合共1000万股本公司股份(股份)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449782.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1600","BK1593","BK1515","00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640597503","title":"医美概念承压 巨子生物(02367)领跌4.08% 机构指敷料药店渠道红利消退、行业进入存量竞争","url":"https://stock-news.laohu8.com/highlight/detail?id=2640597503","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640597503?lang=zh_cn&edition=full","pubTime":"2026-06-03 13:39","pubTimestamp":1780465177,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医美概念普跌，截至发稿，巨子生物(02367)跌4.08%，医思健康(02138)跌3.66%，复星医药(02196)跌3.16%，康哲药业(00867)跌2.53%，四环医药(00460)跌2.08%，三生制药(01530)跌2.07%。消息面上，华龙证券新近研究指，当前医美行业政策端医保支付监管收紧，医美敷料药店渠道红利消退，行业合规化监管持续深化；医美行业进入存量竞争，循证诊疗、合规经营、精细化运营成为机构发展核心方向。产业端AI智能设备、数字化服务加速在美业线下场景渗透，数智化转型成为行业新趋势，区域美业展会加速全产业链资源整合与模式创新。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250110/MDc3ODQ0ZjRmZjY3NDY3NWE2ZmExZWEzMjkyYmRjMmI4NjI3MTMyNDA2NzU1.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MDc3ODQ0ZjRmZjY3NDY3NWE2ZmExZWEzMjkyYmRjMmI4NjI3MTMyNDA2NzU1.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1982967","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00867","BK1207","IE00BVYPNQ40.USD","01530","02138","SG9999015986.USD","HK0000165453.HKD","02196","BK1515","BK1511","BK1161","IE00BYV24P56.USD","SG9999004220.SGD","IE00BVYPNP33.GBP","BK1600","SG9999015945.SGD","BK1593","BK1583","IE00BGHQDM52.EUR","BK1215","BK1191","LU2488822045.USD","00460","SG9999015978.USD","SG9999004311.SGD","IE00BMCWC346.EUR","SG9999015952.SGD","02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109734492","title":"四环医药公布2026年5月股份变动月报表，股本规模保持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1109734492","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109734492?lang=zh_cn&edition=full","pubTime":"2026-06-01 16:32","pubTimestamp":1780302740,"startTime":"0","endTime":"0","summary":"四环医药控股集团有限公司于2026年6月1日发布截至2026年5月31日的月度证券变动报告。报告显示，公司法定股本与注册股本在本期保持不变，法定/注册股本为100,000,000,000股，每股面值HKD0.01，注册资本HKD1,000,000,000。公司当月在5月13日和5月18日分别以HKD1.0931和HKD1.0685回购普通股各10,000,000股，回购股份目前以库存股份形式持有，尚未注销。截至本月末，相关购股权未发生新的授出、行使或失效。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638665795","title":"四环医药(00460)与深原质药签署合作协议 深化AI在医美全产业链及新药研发的战略布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2638665795","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638665795?lang=zh_cn&edition=full","pubTime":"2026-05-28 16:39","pubTimestamp":1779957588,"startTime":"0","endTime":"0","summary":"本次合作标志着本集团在“AI+医美”创新赛道的战略布局迈入全面落地执行的新阶段。合资公司的核心使命是探索与开发AI驱动的生物大分子、高分子等新型医美材料及相关产品，并应用AI赋能医美全产业链。此外，合资公司将与深原质药协同，共同探索利用AI技术设计开发全新的蛋白及核酸药物，发掘新的增长机遇。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447123.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","ARTY","CHAT","AGIX","BK1600","BK1593","00460","AIPO","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638868377","title":"四环医药(00460)：受托人就股份奖励计划购买合共800万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2638868377","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638868377?lang=zh_cn&edition=full","pubTime":"2026-05-27 21:21","pubTimestamp":1779888060,"startTime":"0","endTime":"0","summary":"智通财经APP讯，四环医药(00460)发布公告，于2026年5月27日，受托人已就股份奖励计划于市场上购买合共800万股本公司股份(股份)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446859.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"四环医药(00460)：受托人就股份奖励计划购买合共800万股","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1593","BK1600","00460","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159897116","title":"四环医药于2026年5月18日以每股1.0685港元回购1000万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1159897116","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159897116?lang=zh_cn&edition=full","pubTime":"2026-05-18 21:25","pubTimestamp":1779110749,"startTime":"0","endTime":"0","summary":"2026年5月18日，四环医药控股集团有限公司宣布，于当日以每股1.0685港元的价格，回购了1000万股公司股份。此次股份回购是公司资本管理策略的一部分，旨在优化股本结构，并可能向市场传递管理层对公司内在价值及未来前景抱有信心的积极信号。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","BK1593","BK1515","BK1191","BK1600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118310613","title":"四环医药回购1000万股股份，总额约1,068.50万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1118310613","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118310613?lang=zh_cn&edition=full","pubTime":"2026-05-18 18:02","pubTimestamp":1779098535,"startTime":"0","endTime":"0","summary":"四环医药（股票代码：00460）于2026年5月18日公告，已于香港联交所场内回购合计1000万股股份，占公司现有已发行股本约0.1095%。回购价格介乎每股1.05港元至1.08港元，总金额约1,068.50万港元。\n回购完成后，公司已发行股本变动为9,125,988,206股，并持有库存股份204,011,000股。购回授权由公司于2025年6月6日通过，剩余可回购股份至921,358,420股。公司确认已遵守相关上市规则及适用法律规定。\n本公告由执行董事及联席公司秘书陈燕玲签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"四环医药回购1000万股股份，总额约1,068.50万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636211400","title":"四环医药(00460)5月18日斥资1068.5万港元回购1000万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2636211400","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636211400?lang=zh_cn&edition=full","pubTime":"2026-05-18 17:55","pubTimestamp":1779098139,"startTime":"0","endTime":"0","summary":"智通财经APP讯，四环医药(00460)发布公告，于2026年5月18日，该公司斥资1068.5万港元回购1000万股股份，每股回购价1.05-1.08港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442969.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","00460","BK1515","BK1191","BK1600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636048086","title":"创新药概念走软 药明合联(02268)领跌5.57% 机构成仍看好以创新为主医药科技主线","url":"https://stock-news.laohu8.com/highlight/detail?id=2636048086","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636048086?lang=zh_cn&edition=full","pubTime":"2026-05-18 10:09","pubTimestamp":1779070152,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念整体走软，截至发稿，药明合联 跌5.57%，亚盛医药-B跌5.50%，四环医药跌4.55%，康方生物跌4.49%，歌礼制药-B跌4.36%，同源康医药-B跌4.31%，康诺亚-B跌4.24%，荣昌生物跌4.14%。展望2026年，该机构继续看好以创新为主的医药科技主线，重点关注创新药、脑机接口、AI医疗、手术机器人等，同时建议布局2026年行业有望迎来反转的老龄化及院外消费，关注估值较低的麻药、血制品、中药等。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981521","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417516738.SGD","LU2399975544.HKD","BK1587","LU2778985437.USD","LU2476274308.USD","01672","LU0417516902.SGD","BK1515","BK1191","09995","00460","09926","IE00B543WZ88.USD","BK1600","02410","BK1583","LU0561508036.HKD","LU0417516571.SGD","06855","BK1574","LU0348783233.USD","BK1141","159938","LU1969619763.USD","BK1161","LU0634319403.HKD","06978","IE00B5MMRT66.SGD","02162","LU0348784397.USD","BK1593","LU0348767384.USD","IE00BPRC5H50.USD","LU1794554557.SGD","159992","LU0540923850.HKD","LU0348825331.USD","LU0348735423.USD","02268","LU0348827113.USD","LU1961090484.USD","SG9999014674.SGD","LU0348766576.USD","LU2488822045.USD","LU2328871848.SGD","LU1720050803.USD","LU2476274720.SGD","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635832517","title":"四环医药(00460)5月13日斥资1093.1万港元回购1000万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2635832517","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635832517?lang=zh_cn&edition=full","pubTime":"2026-05-13 18:37","pubTimestamp":1778668627,"startTime":"0","endTime":"0","summary":"智通财经APP讯，四环医药(00460)发布公告，于2026年5月13日斥资1093.1万港元回购1000万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441278.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","00460","BK1600","BK1593","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633435190","title":"四环医药(00460)建议采纳2026年股权激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2633435190","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633435190?lang=zh_cn&edition=full","pubTime":"2026-05-08 16:37","pubTimestamp":1778229448,"startTime":"0","endTime":"0","summary":"智通财经APP讯，四环医药(00460)发布公告，于2026年5月8日，董事会建议采纳2026年股权激励计划。2026年股权激励计划将构成香港联合交易所有限公司证券上市规则第十七章项下之股份计划，且其条文将符合其项下之规定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439534.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00460","BK1600","BK1515","BK1593","BK1191"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sihuanpharm.com.cn","stockEarnings":[{"period":"1week","weight":0.0233},{"period":"1month","weight":0.0244},{"period":"3month","weight":-0.3252},{"period":"6month","weight":-0.3353},{"period":"1year","weight":-0.3303},{"period":"ytd","weight":-0.2757}],"compareEarnings":[{"period":"1week","weight":0.0163},{"period":"1month","weight":0.0662},{"period":"3month","weight":-0.0391},{"period":"6month","weight":-0.0668},{"period":"1year","weight":-0.0274},{"period":"ytd","weight":-0.026}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"四环医药控股集团有限公司是一家主要从事研发、制造及销售医药产品和医美产品的投资控股公司。该公司通过三个分部运营其业务。医美产品分部包括填充类、塑形类、支撑类、补充类、光电设备类、体雕类、皮肤管理类及其他以及提供轻医美综合解决方案。创新药及其他药品分部从事研发及商业化糖尿病、乳腺癌、消化、肿瘤及非酒精性脂肪型肝炎等疾病领域的创新药。仿制药分部从事包括克林澳等仿制药的生产和销售。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.119713},{"month":2,"riseRate":0.5,"avgChangeRate":0.000651},{"month":3,"riseRate":0.3125,"avgChangeRate":-0.032043},{"month":4,"riseRate":0.533333,"avgChangeRate":0.038601},{"month":5,"riseRate":0.4,"avgChangeRate":0.003084},{"month":6,"riseRate":0.533333,"avgChangeRate":-0.005353},{"month":7,"riseRate":0.6,"avgChangeRate":0.01117},{"month":8,"riseRate":0.5,"avgChangeRate":-0.014605},{"month":9,"riseRate":0.214286,"avgChangeRate":-0.045139},{"month":10,"riseRate":0.571429,"avgChangeRate":0.02973},{"month":11,"riseRate":0.466667,"avgChangeRate":0.008336},{"month":12,"riseRate":0.4,"avgChangeRate":-0.017751}],"exchange":"SEHK","name":"四环医药","nameEN":"SIHUAN PHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"四环医药(00460)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供四环医药(00460)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"四环医药,00460,四环医药股票,四环医药股票老虎,四环医药股票老虎国际,四环医药行情,四环医药股票行情,四环医药股价,四环医药股市,四环医药股票价格,四环医药股票交易,四环医药股票购买,四环医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"四环医药(00460)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供四环医药(00460)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}